Navigation Links
Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
Date:8/20/2012

CAMBRIDGE, Mass., Aug. 21, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals Inc. (Inspiration) today announced new license, development and commercialization agreements with its strategic partner, Ipsen (Euronext: IPN, ADR: IPSEY). The agreements restructure the existing partnership with Ipsen and provide Inspiration with additional funding to support development of its two investigational drugs in late-stage development for hemophilia, IB1001 and OBI-1. Under the terms of these agreements, Inspiration grants Ipsen commercialization rights for IB1001 (recombinant human factor IX) and OBI-1 (recombinant porcine factor VIII) in certain geographies. Inspiration will receive a $30 million up-front payment, with additional payments and investments linked to future development and commercial milestones, for a total potential value of $200 million. This includes a commitment from Ipsen to fund a significant percentage of Inspiration's next round of external financing.

Ipsen gains rights to commercialize IB1001 and OBI-1 in Europe, Russia, China, Australia and certain other countries, and will be responsible for future regulatory filings in those regions. Inspiration retains commercialization rights in the Americas, Japan, India, the Middle East, South Africa, Taiwan and certain other countries, as well as global development rights for all products in Inspiration's product portfolio. Each company is obligated to pay the other royalties generated by sales of OBI-1 in their respective geographies and Ipsen will pay Inspiration royalties on sales of IB1001.

Under the terms of the new agreements, after the completion of a $30 million qualified external financing Ipsen will invest an additional $20 million in Inspiration and will no longer have a call option to acquire Inspiration, giving Inspiration the ability to develop as an independent entity. Ipsen gains the right to appoint two additional Directors to Inspiration's Board.

"Durin
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
2. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
3. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
4. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
5. Global Biopharmaceuticals Market 2011-2015
6. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
11. Response Genetics, Inc. Announces Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... Indianapolis, IN (PRWEB) , ... July 01, 2015 , ... ... the 2015 BIO International Convention in Philadelphia, PA. , The presentation took ... milestones and outlined the plans for the development of APX3330 for the treatment of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty from Beijing ... half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from ... combines students from both universities and is taught on both continents. , “Our ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... ARUP Laboratories, pathologist, Ronald L. Weiss, MD, MBA, ... of American Pathologists at CAP ,11, the organization,s annual ... the CAP, the award honors members "who have made ... the specialty of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ...
... BEACH, Fla., Nov. 9, 2011 Biotech developer Divine ... which has been expanding the topical hair-growth segment, is ... system, Polaris API Solution 9, to be supplied by ... With well-established materials like minoxidil sulfate, finasteride, alfatradiol, ...
... Nov. 9, 2011 Third Quarter Highlights ... Awarded $5.7 million contract from Department of Defense (DoD) for ... awarded PharmAthene 50% net profit split on worldwide sales of ... million in net profits Completed 1500L commercial scale-up and ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians 2Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians 3PharmAthene Reports Third Quarter 2011 Financial and Operating Results 2PharmAthene Reports Third Quarter 2011 Financial and Operating Results 3PharmAthene Reports Third Quarter 2011 Financial and Operating Results 4PharmAthene Reports Third Quarter 2011 Financial and Operating Results 5PharmAthene Reports Third Quarter 2011 Financial and Operating Results 6PharmAthene Reports Third Quarter 2011 Financial and Operating Results 7PharmAthene Reports Third Quarter 2011 Financial and Operating Results 8
(Date:6/15/2015)... -- A new report [ 1 ... US consumers using mobile banking applications want their mobile devices ... voiceprint, instead of having to prove who they are with ... Identity   -   The Fusion of Financial Services, Mobile ... primary channel used by Gen X and Gen Y to ...
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
(Date:6/9/2015)... , June 09, 2015 Research ... addition of the "Gesture Recognition & Touchless ... (Consumer Electronics, Automotive, & Others), Product (Biometric & ... to 2020" report to their offering. ... market is expected to reach $ 23.55 Billion ...
Breaking Biology News(10 mins):One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... , Oct. 21, 2013   Arcturus Therapeutics, Inc. , an industry ... today announced it has secured $5 million in a Series A ... Canada , Japan and ... http://photos.prnewswire.com/prnh/20130531/MM24393LOGO ) The Series A funding, which comprised ...
... MA In a biological quirk that promises to ... potentially treating Fragile X syndrome, scientists at the University ... out a gene important for messenger RNA (mRNA) translation ... in a mouse model of a prevalent human neurological ...
... Jude Children,s Research Hospital scientists has linked an inherited ... developing a pediatric acute lymphoblastic leukemia (ALL) subtype that ... today in the online edition of the scientific journal ... found in the GATA3 gene. Researchers reported the high-risk ...
Cached Biology News:Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 2Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 32 genetic wrongs make a biochemical right 22 genetic wrongs make a biochemical right 32 genetic wrongs make a biochemical right 4Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse 2Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse 3
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 19 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
... array sample elements. , ,Includes: , DiscoverLight ... BSA in PBS (10X): 50 ml , ... , BupH Phosphate Buffered Saline: 8 packs ... ml ampules , SuperSignal West Pico Luminol Enhancer: 2 ...
Biology Products: